Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03935984 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 19, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Lead sponsor: ProMedica Health System to Joseph Sferra
    • Primary completion date: Apr 1, 2021 to Jun 1, 2026
    • Study completion date: Oct 1, 2021 to Dec 31, 2026
    v4
  2. Phase: Not applicable to Phase 4
    • Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 20, 2019 to May 29, 2019
    v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.
Trial Details
NCT Number NCT03935984
Lead Sponsor Joseph Sferra
Collaborators: University of Toledo Health Science Campus
Conditions
(from sponsor)		 Primary Hyperparathyroidism, Hypercalcemia
Related terms Hypercalcemia, Hyperparathyroidism, Primary
Enrollment 37 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov